CPA
CRBU icon

Capital Performance Advisors’s Caribou Biosciences CRBU Stock Holding History

Capital Performance Advisors’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-675
Closed -$1.32K – 730
2024
Q3 		$1.32K Buy
+675
New +$1.38K ﹤0.01% 1769

Other funds holding CRBU

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Performance Advisors's CRBU Position: Q4 2024 in Review

Capital Performance Advisors sold out of Caribou Biosciences (CRBU) in Q4 2024, closing a stake of 675 shares — an estimated $1.32K sold.

Capital Performance Advisors first reported a position in CRBU in Q3 2024 and held it in 1 quarter. The position peaked at $1.32K in Q3 2024. 133 funds tracked by Wall St. Rank hold CRBU as of Q4 2024.

  • Capital Performance Advisors reported no remaining Caribou Biosciences position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 675 Caribou Biosciences shares in Q4 2024, an estimated $1.32K.
  • Capital Performance Advisors first reported a position in Caribou Biosciences in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Caribou Biosciences position peaked at $1.32K in Q3 2024.
  • 133 funds tracked by Wall St. Rank held Caribou Biosciences as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.